Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

n the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have shown that M6G given intravenously produces equivalent analgesia to morphine to combat post-operative pain. Studies have also shown that M6G reduced the incidence of nausea and vomiting when compared directly with morphine. Other studies published recently in the scientific literature demonstrate that M6G also reduces respiratory depression compared to morphine.

M6G022 Study Design

The study involved 24 centres in six European countries and recruited 517 patients. The study was designed primarily to provide key information on a comparison of effective intravenous pain management regimens of M6G or morphine treatment for a minimum of 24 hours (and up to 48 hours) following major abdominal surgery. Morphine is generally accepted as the "gold standard" drug for use in these circumstances. Initial pain management was achieved by administration of a loading dose and titration of either M6G or morphine to achieve acceptably low levels of pain for the patient to go onto the ward. In the ward, pain management treatme
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... in two upcoming investor conferences. On Tuesday, ... th Annual Piper Jaffray Healthcare Conference.  D. ... provide an update on the company beginning at 11:30 ...
(Date:11/26/2014)... , Nov. 26, 2014  Genomic Health, Inc. ... Popovits , Chairman, Chief Executive Officer and President, will ... Healthcare Conference at The New York Palace Hotel in ... 3 at 11:30 am Eastern Time (ET). ... the conference call, go to the  Investor Relations  section ...
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... findings of the first cost-effectiveness analysis of Vimpat® ... partial-onset seizures.  The findings were presented at the ... (ISPOR) annual meeting in Baltimore, MD, USA.   ... to analyze standard anti-epileptic drug therapy with and ...
... Pa., May 31, 2011 CSL Behring ... Designations (ODD) by the European Commission for the development of ... (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia ... to exclusively market recombinant factor VIIa fused with albumin in ...
Cached Medicine Technology:New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V 2New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V 3New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V 4New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V 5New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V 6New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V 7New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V 8CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment 2CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment 3CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment 4
(Date:11/27/2014)... Dr. Ronald Receveur, who has a leading Southern ... health tips before patients dig into the annual Thanksgiving feast. ... Albany affordable cosmetic dentistry, and his staff understand that ... While the staff wishes everyone a happy and safe holiday, ... can enjoy a feast that is also healthy on their ...
(Date:11/27/2014)... At The Little Gym, we know that being ... surprise when a recent study confirmed that regular physical ... Journal of Pediatrics found that “Promoting physical activity ... school years may be important not only for health, ... two groups of children; those that were engaging in ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, an ... will provide a 10% Christmas discount on PPC service. The ... The discount offer will begin on 1 December 2014 and ... About this offer, a PPC professional working at Ethane Web ... for small businesses, as this big discount would make the ...
(Date:11/26/2014)... 2014 AlignLife, a chiropractic and ... kick-off of its annual Toy Drive. With the ... to donate to those in need throughout their ... to distribute the donations to those most in ... will be accepting donations at the clinics to ...
(Date:11/26/2014)... Sweetdressy.com, the well-known wedding dress manufacturer for the global ... dresses for ladies worldwide. Meanwhile, these graceful items are ... are very popular in the world and clients can ... , Sweetdressy.com believes that a company can attract ... and best services. The spirit of the company is ...
Breaking Medicine News(10 mins):Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2Health News:Cheap Prom Dresses For Ladies Introduced At SweetDressy.com 2
... New Dynamics of Ageing Programme (NDA), a collaboration between ... and Humanities Research Council, the Biotechnology and Biological Sciences ... the Economic and Social Research Council and the Medical ... applications to be funded under the programme. , ...
... Oct. 18 ReBuilder,Medical Technologies, Inc. (Pink ... by world-renowned medical device inventor David B.,Phillips, ... service organization and facilitation. (Logo: ... when many companies are outsourcing customer service ...
... Cost of Prescription Drugs, WASHINGTON, Oct. 18 ... following statement in response to,today,s House Judiciary Committee ... independent pharmacists sweeping antitrust,exemptions:, "This bill couldn,t ... and,consumers alike. As most everyone is searching for ...
... UK awarding body associated with hairdressing and beauty therapy ... a major UK Centre for Burns Research based at ... of its kind by The Vocational Training Charitable Trust ... pioneering research programme soon to start in South Wales. ...
... Children Under 5 in Madagascar to Sleep Under Bed ... More and,Sumitomo Chemical have teamed up to contribute to ... Madagascar between October 22-29. Led by the Malagasy ... six months to five years old receives a bed ...
... The Bayer Foundation,announced today it has awarded ... of Chemical & Biomolecular Engineering (UH CHBE) to,establish ... which is competitive with other prestigious fellowships,from the ... over a,three-year period to a graduate student pursuing ...
Cached Medicine News:Health News:Research for a better old age 2Health News:Research for a better old age 3Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 2Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 3Health News:£1 million donation for burns research in Wales 2Health News:Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria 2Health News:Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria 3Health News:Bayer Foundation Grant Creates Graduate Engineering Fellowship at University of Houston 2Health News:Bayer Foundation Grant Creates Graduate Engineering Fellowship at University of Houston 3
... Improved Access in Open Procedures ... ,The ENDOPATH ETS Compact-Flex45 No-Knife Articulating ... a 45mm staple line for open ... either a standard blue cartridge, a ...
... The ETS45 and ETS-FLEX45 ... 45mm staple and cut line. ... the device suitable for many ... cutters are intended for transection, ...
... Auto Suture ENDO CLIP 5 mm ... The applier is designed for introduction ... Auto Suture trocar sleeve, or larger ... The overall length of the shaft ...
Insert only, Pilling-Weck medium clip size...
Medicine Products: